Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma

Carole Soussain, Samar Issa, Katharine L Lewis, Christian Grommes, Judith Fox, Renee Ward, Caryn Peterson, Matt Cravets, Anita Mathias, Judith Sosa, Brian J Kirby, Zhaoqing Ding, Isharat Yusuf, Mark J Rose, Marcos W Steinberg, Han W. Tun

Research output: Contribution to journalArticlepeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)12068-12069
JournalBlood
Volume140
Issue numberSupplement 1
DOIs
Publication statusPublished - Nov 2022
Externally publishedYes

Cite this